FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine Post author:PacConAdmin Post published:July 15, 2025 Post category:Uncategorized Post comments:0 Comments FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine Source: FDA Press Releases Tags: aaps Read more articles Previous PostFDA Approves Gardenia (Genipin) Blue Color Additive While Encouraging Faster Phase-Out of FD&C Red No. 3 Next PostFDA to Revoke 52 Obsolete Standards of Identity for Food Products You Might Also Like Biosimilars Face Hurdles of Clinician, Patient Acceptance After Gaining FDA Approval October 3, 2023 FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients July 28, 2025 Dream Sock Baby Monitor, Renal Denervation to Control Blood Pressure Get FDA Nods November 9, 2023 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.